Researchers at Linköping University are now launching a plan to effectively treat psoriasis.
About 300 000 Swedes suffer from the difficult to treat disease, which manifests itself in scaly and often itchy patches on the skin. The reason is that cells divide without restraint as new blood vessels form in the deeper layers of the skin.
An important component is the psoriasin protein (S100A7), which are abundant in psoriasis-affected skin but rarely in normal skin. The same protein is also assumed to be a factor in the development of breast cancer. The research team, led by associate professor Charlotta Enerbäck, have now illustrated that, in a study on cultured skin cells, the interaction between psoriasin, oxygen free radicals and vascular endothelial growth factors (VEGF) leads to significantly increased cell division and growth of new blood vessels (angiogenesis). When we blocked the formation of psoriasin, the expression of VEGF also decreased.
Published in the journal Breast Cancer Research and Treatment, the results open new possibilities for the effective treatment of this crippling disease.
“We want to examine the ability of psoriasin as a target for therapy. By inhibiting psoriasin, we believe we can reduce vascular formation and thus the proliferation of the disease’s magnitude and intensity,” says Charlotta Enerbäck.
Previous studies in mice have shown that angiogenesis inhibitors reduce not only neovascularization but also inflammation and excessive cell division. Attempts to inhibit the growth factor VEGF have resulted in unwanted side effects because it exists in normal tissue where it contributes to wound healing.
“Since psoriasin expresses itself specifically only in the diseased psoriatic skin, we expect that inhibitors against this are highly selective and effective against the disease, and that the risk for side effects is minimal,” says Charlotta Enerbäck.
Presently, palliative treatments with vitamin D, cortisone, light and low doses of chemotherapy are used. More recently, some “biological”, antibody-based drugs arrived on the market, however they are very expensive and not free from side effects.
The study was supported by grants from the
- Swedish Cancer Society
- The Swedish Psoriasis Association
- The Assar Gabrielsson Foundation
- The Welander Foundation
- The Tore Nilsson Foundation
Psoriasin (S100A7) Increases the Expression of ROS and VEGF and Acts through RAGE to Promote endothelial cell proliferation by Emman Shubbar, Jenny Vegfors, Mary Carlström, Stina Petersson and Charlotta Enerbäck. Breast Cancer Research and Treatment online 21 December 2011.
Charlotta Enerbäck +46 (0) 101 037 429, +46 (0) 734 607 131
Åke Hjelm 2012-01-09